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Nonserotypeable pneumococci (NSP) are commonly carried by Australian Indigenous children in remote
communities. The purpose of this study was to characterize carriage isolates of NSP from Indigenous children
vaccinated with the seven-valent pneumococcal conjugate vaccine (PCV7) and to use these data to guide
decisions on reporting of NSP. A total of 182 NSP were characterized by BOX typing, antibiogram analysis, and
multilocus sequence typing (MLST) of common BOX types. NSP positive for the wzg capsule gene were
analyzed by a multiplex PCR-based reverse line blot hybridization assay (mPCR/RLB-H) targeting capsule
genes to determine the serotype. Among 182 NSP, 49 BOX types were identified. MLST of 10 representative
isolates found 7 STs, including ST448 (which accounted for 11% of NSP). Non-penicillin susceptibility was
evident in 51% of the isolates. Pneumococcal wzg sequences were detected in only 23 (13%) NSP, including
10 that contained an 1.2-kb insert in the region. mPCR/RLB-H identified serotype 14 wzy sequences in
all 10 NSP, and 1 also contained a serotype 3-specific wze sequence. Among the remaining 13 wzg-positive
NSP, few belonged to the serotypes represented in PCV7. It appears that most NSP identified in Australian
Indigenous children are from a true nonencapsulated lineage. Few NSP represented serotypes in PCV7
that suppress capsular expression. High rates of carriage and penicillin resistance and the occasional
presence of capsule genes suggest a role for NSP in the maintenance and survival of capsulated pneu-
mococci. To avoid the inflation of pneumococcal carriage and antibiotic resistance rates, in clinical trials,
we recommend separate reporting of rates of capsular strains and NSP and the exclusion of data for NSP
from primary analyses.
Australian Indigenous children in remote communities of
the Northern Territory experience dense, persistent naso-
pharyngeal colonization with Streptococcus pneumoniae
(pneumococcus) from early infancy (13, 25). Cross-sectional
studies report pneumococcal carriage rates of over 80% for
these children (15). Pneumococcal serotype diversity con-
tributed to swift serotype replacement following introduc-
tion of the seven-valent pneumococcal conjugate vaccine
(PCV7) in 2001. The vaccine had no significant impact on
the incidence of overall pneumococcal carriage or otitis
media (14).
To date, 91 pneumococcal serotypes have been described
(21). In addition, a population of nonserotypeable pneumo-
coccal (NSP) isolates does not react with the capsular poly-
saccharide typing sera. Molecular typing has identified three
categories of NSP: (i) pneumococci that lack capsule genes,
(ii) pneumococci that possess capsule genes but that are
phenotypically nonencapsulated, and (iii) atypical pneumo-
cocci that are phenotypically NSP but that are genetically
divergent from pneumococci (8,18). Pneumococci that lack
capsule genes make up a highly diverse population that
includes strains that have spread globally (8). These strains
have been associated with a variety of mucosal (and, occa-
sionally, invasive) diseases (for a review, see reference 24).
Phenotypically nonencapsulated pneumococci that possess
capsule genes may represent pneumococci that have lost the
ability to express the capsule or strains that have tempo-
rarily ceased or downregulated capsule expression. Under-
standing the distinction between these populations is par-
ticularly important in the context of widespread immuniza-
tion with anticapsular vaccines.
NSP frequently colonize Indigenous Australian children. In
our studies with young Indigenous children, NSP were de-
tected in up to 18% of nasopharyngeal swab specimens. In a
recent cross-sectional carriage study, NSP were the 3rd most
common pneumococcal serotype (unpublished data from ref-
erence 16). It is also likely that we underestimate NSP carriage
rates because of their morphological differences from their
capsular counterparts; NSP tend to be smaller and dryer than
capsular pneumococci, and the dimple is less conspicuous. The
purpose of this study was to characterize NSP carriage isolates
collected from Indigenous children after the introduction of
PCV7. Our aim was to understand the potential importance of
this population, particularly with regard to the presence of the
capsule genes and antibiotic resistance. Importantly, we re-
quire evidence to guide reporting of NSP carriage and resis-
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tance in pneumococcal surveillance studies and as microbio-
logical outcomes in clinical trials for otitis media.
MATERIALS AND METHODS
Ethics. Ethical approval for this study was granted by the Human Research
Ethics Committee of the Northern Territory Department of Health and Families
and the Menzies School of Health Research. Isolates were selected only if the
parents or guardians consented at enrollment to the samples being used for
future research.
Definition of NSP. NSP were grown on horse blood agar plates (Oxoid,
Australia) at 37°C in 5% CO2 and identified as optochin sensitive, alpha-hemo-
lytic colonies with a negative reaction to Quellung omniserum (1) and a positive
autolysin (lytA) PCR result (19).
Samples. A total of 182 nasopharyngeal NSP isolates were randomly selected
(Research Randomizer; http://www.randomizer.org) from four studies of otitis
media (Table 1) conducted in the Northern Territory after the introduction of
PCV7. The isolates were stored at 80°C in skim milk-tryptone-glucose-glycerol
broth (20). When the specimens originated from longitudinal studies, sample
selection was limited to the first NSP isolate recovered from each child.
Antibiotic susceptibility testing. Screening for penicillin and macrolide sus-
ceptibility was determined by a calibrated dichotomous susceptibility (CDS) disk
diffusion assay (oxacillin and erythromycin, respectively) (3). Etests (AB Biodisk,
Solna, Sweden) were used to determine the penicillin and erythromycin MICs of
all nonsusceptible isolates (CDS radius  6 mm). PCR for the detection of
macrolide resistance genes (mefA/E and ermB was performed as described pre-
viously (18, 26).
DNA extraction and quantification. NSP DNA for BOX typing and the de-
tection of macrolide resistance genes was extracted by using the Instagene matrix
(Bio-Rad), according to the manufacturer’s instructions. NSP DNA for multilo-
cus sequence typing (MLST) was extracted with a QIAamp DNA minikit
(Qiagen), according to the manufacturer’s instructions. The DNA concentration
was determined with a Picogreen double-stranded DNA quantitation assay kit
(Molecular Probes). The extraction of DNA for multiplex PCR/reverse line blot
hybridization (mPCR/RLB-H) was done as described previously (12).
Capsule gene PCR. The capsule gene was detected by the method of Hanage
et al. (8), with the exception that primers wzg-up (5-ATCCTTGTCAGCTCTG
TGTC) and wzg-down (5-TCACTTGCAACTACATGAAC) amplified a
1,797-bp product.
Molecular typing. BOX typing was done as described previously with 1 ng of
DNA in each 50-l reaction mixture (27). The BOX types were defined accord-
ing to the banding patterns between 750 bp and 3,000 bp. MLST was undertaken
essentially as described previously (6), except for modification of the spi forward
primer (primer spiF3, 5-CAGATTTTGCAAGCCTATGG), the recP reverse
primer (primer recPR2, 5-GCCGTGTACAGCATTAGTTC), and the ddl for-
ward primer (primer ddlF2, 5-GATGGCTCTGTTCAAGGATT). Molecular
serotyping of wzg-positive isolates of NSP was by done mPCR/RLB-H, as de-
scribed previously (11, 28), for 90 pneumococcal serotypes. This method targets
serotype-specific regions of wzy for all serotypes with the exception of serotype 3.
In the case of serotype 3, wze is targeted, as wzy is not present in serotype 3
strains.
RESULTS
NSP colonization of Indigenous children. Presumptive NSP
in this study were identified on the basis of colonial morphol-
ogy, optochin sensitivity in 5% CO2 for distinction from S.
pseudopneumoniae (2), and a negative Quellung reaction. In
longitudinal studies 1 and 2 (Table 1), presumptive NSP were
reported in 18% and 8% of the nasopharyngeal swab speci-
mens, respectively. Cross-sectional studies 3 and 4 reported
presumptive NSP carriage prevalence rates of 8% and 5%,
respectively. These numbers are likely to underestimate the
true carriage rate because NSP were not systematically sought.
Variations in the rates reported between studies may also be
due to subjectivity in the selection of colonies.
Characterization of NSP by BOX typing and antibiogram
analysis. Among the 182 randomly selected isolates of NSP
(which were confirmed to be lytA positive), 49 BOX types were
identified. The three most common BOX types (types 1, 14,
and 3) represented 44% of the isolates. BOX types 1 and 14
were closely related, distinguished by a single band size differ-
ence of less than 50 bp.
Intermediate resistance to penicillin (MICs, 0.12 to 1 g/ml;
breakpoint for oral therapy of nonmeningeal strains) was evi-
dent in 49% (90/182) of the NSP isolates, penicillin resistance
(MICs, 2 g/ml) was detected in 2% (4/182) of the isolates,
and erythromycin resistance (MICs,4 g/ml) was detected in
10% (19/182) of the isolates. Erythromycin resistance was me-
diated by the mefE macrolide resistance gene in all except one
of the isolates; the latter isolate was negative for the mefA/E
and ermB genes. Reduced susceptibility to these commonly
used antimicrobials was detected in isolates from 32 BOX
types.
Characterization of NSP by MLST. Representative isolates
of the three most common BOX types, including all antibio-
grams, were analyzed by MLST (Table 2). BOX type 1 and 14
isolates were represented by six sequence types (STs), all of
which were new to the MLST database. Two STs were com-
mon to these BOX types. ST4485 was a double-locus variant of
a single ST corresponding to a serotype 4 isolate. ST4487 and
ST4488 were both double-locus variants of two STs corre-
sponding to serotype 14 and 19A isolates. The BOX type 3
isolate was ST448, an NSP clone reported internationally.
TABLE 1. Carriage study details
Study Description (reference)a Yr(s) No. of subjectsenrolled
No. of swabs (nasal or
nasopharyngeal)
Age at
enrollment (mo)
Median Range
1 Longitudinal carriage study of infants receiving
PCV7 and 23PPVain three communities (17)
2001–2004 97 914 (two to four weekly to 1
yr, 18 mo, and 24 mo)
1.13 0.23–7.96
2 RCT of azithromycin vs amoxicillin for AOM
in 16 communities (in press)
2003–2005 320 661 (days 0, 6–11, and 12–21
if AOM with perforation
was present)
13 5.9–71.8
3 Cross-sectional carriage surveys in four
Indigenous communitiesb (16)
2002 192 212 85.7 24–188
4 Cross-sectional carriage surveillance of 2003 902 902 21.3 0.76–75
children ages 0 to 6 yr in 29 (2003) and 17
(2005) communities (15)
2005 818 818 33.7 0.36–72
a 23PPV, 23-valent pneumococcal polysaccharide vaccine; RCT, randomized controlled trial; AOM, acute otitis media.
b Children 16 years of age were included.
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ST448 and STs 4486, 4484, and 4565 were not closely related
(less than five identical MLST loci) to STs corresponding to
capsular pneumococci that are currently in the MLST data-
base. All isolates were confirmed to be pneumococci by using
the “is it a pneumococcus?” analysis (www.mlst.net).
Presence of wzg gene. As described previously (8), we used
PCR for the conserved wzg (cpsA) gene to test for the presence
of a cps locus (Tables 3 and 4). wzg was detected in 23 of 182
(13%) NSP isolates and 13 BOX types. However, 10 isolates
provided a product of approximately 3 kb rather than the
expected 1.8-kb product. Partial sequencing of the product
demonstrated a sequence homologous to that of the pneumo-
coccal wzg gene and an unidentified insert which was not re-
lated to streptococcal ali genes, as reported previously (9). The
10 isolates represented four different BOX types, suggesting
that this insertion was not a recent event.
mPCR/RLB-H analysis of the isolates with the expected
1.8-kb wzg gene determined that five isolates corresponded to
PCV7 serotypes 9V (or 9A) and 14, whereas eight corre-
sponded to non-PCV7 serotypes 7A/F, 16F, 11A/D, 22A/F, and
13 (Table 3). Cocolonization with a capsular strain of the
corresponding serotype was evident for 8 of 13 NSP with the
1.8-kb wzg product (Table 3). Subsequent testing of all strains
with specific type antisera found that none reacted.
mPCR/RLB-H analysis determined that the 10 isolates with
the 3-kb wzg PCR product corresponded to serotype 14. Two
BOX type 14 isolates positive for the insertion were ST4488
(double-locus variants of STs corresponding to serotype 14 and
19A isolates).
One isolate consistently provided a serotype 14 result (based
on the result for wzy) and a serotype 3 result (based on the
result for wze), suggesting mosaicism of the strain and that
both serotype 3 and 14 capsular genes may exist in this strain.
Reduced susceptibility to antimicrobials was common in all
groups (Table 4).
DISCUSSION
Australian Indigenous children living in remote communi-
ties experience capsular pneumococcal carriage rates of ap-
proximately 80% and NSP carriage rates of 5 to 20%. These
NSP carriage rates are likely to be underestimates because
NSP are morphologically distinct from capsular pneumococci
and NSP were not systematically sought in the studies that
determined those carriage rates. NSP detection rates in a pop-
ulation appear to be dependent on the study protocol and
subjectivity in colony selection.
Cocolonization with capsular and noncapsular pneumococci
occurred frequently, providing an opportunity for an interac-
tion between these populations. Previous studies of NSP report
a highly diverse population with a pervasive nature, an ability
to cause disease, and a likely important role in pneumococcal
ecology (8, 23, 24). Although nonencapsulated forms are less
likely to cause disease, their ability for gene transfer, including
the transfer of antibiotic resistance and capsular/virulence
genes, is predictably high due to their capacity for an increased
rate of transformation (22).
The majority of NSP are likely to be of the true nonencap-
sulated lineage. Two distinct populations were detected in this
study: NSP with and without the wzg (cpsA) gene. The majority
(87%) of NSP in this study were wzg negative by PCR and were
thus likely to be of the true nonencapsulated lineage. However,
given that 10 of 23 wzg sequences were atypical due to an inser-
tion, we cannot rule out the possibility that other isolates con-
tained modified wzg sequences not detectable by our methods.
Our grant did not provide funding for MLST of all NSP
isolates; however, MLST of representatives of the three most
common BOX types identified authentic pneumococci, includ-
ing six new STs and ST448 (which accounted for 11% of the
NSP in this study). ST448 is a particularly interesting clone, in
that it is internationally disseminated and has been associated
with invasive disease (9).
TABLE 3. Investigation of serotypes associated with
wzg-positive NSPa
BOX type MLST type NSP serotype Simultaneouslycarried serotypes
1.8-kb wzg product
5 11A/11Db 11A
6 7A/7Fb 7F
8 16F 16F
8 16F 16F
14 9A/9Vb 15B
14 9A/9Vb None
14 14 19A
17 22A/22Fb 22F
25 14 19F
30 14 6B
32 13 13
52 16F 16F
57 16F 16F
3-kb wzg product
1 14 None
1 14 19F
1 14 None
13 14 21
14 14 19A
14 14 None
14 14 19A
14 4488c 14 16F
14 4488c 14 and 3d None
15 14 15C
a The serotype of each wzg-positive NSP was determined by mPCR/RLB-H.
Capsular pneumococcal serotypes simultaneously carried in each swab are
shown. PCV7 serotypes are indicated in boldface.
b Pneumococcal serogroups indistinguishable by mPCR/RLB-H.
c Double-locus variant of STs corresponding to serotypes 14 and 19A.
d This isolate reacted with serotypes 14 and 3 by mPCR/RLB-H.
TABLE 2. MLST investigation of the three most
common NSP BOX types
BOX type No. (%) of isolates MLST type(no. of isolates)
1 34 (19) 4485 (1)
4486 (1)
4487 (1)
4488 (1)
14 25 (14) 4484 (1)
4486 (1)
4488 (2)
4565 (1)
3 20 (11) 448 (1)
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Identification of the majority of NSP in this study was based
on colonial morphology, optochin susceptibility, and a positive
lytA PCR result. Therefore, it is likely that these strains were S.
pneumoniae rather than S. pseudopneumoniae (which are gen-
erally optochin resistant in the presence of increased amounts
of CO2) (2) or other closely related Streptococcus spp. How-
ever, as lytA is not ideal as a sole genetic criterion for pneu-
mococcal identification, in due course MLST analysis may
identify some strains as atypical pneumococci (divergent at the
seven MLST loci by 5%) (7).
NSP do not represent a population of PCV7 types suppress-
ing capsule expression. Capsular genes (wzg) were detected in
a minority of the NSP isolates. Ten of these isolates had an
insertion in wzg which may have interrupted capsule expres-
sion, while 13 contained capsule genes related to both PCV7
and non-PCV7 serotypes. Additionally, among 182 isolates,
only 15 were potentially downregulated PCV7 types. These
data do not support the hypothesis that PCV7 types are sup-
pressing capsule expression to avoid vaccine-induced immune
clearance.
NSP may act as a parking lot for antibiotic resistance genes.
Transformation is a common mechanism for the development
of resistance to penicillin and macrolides in pneumococci (4,
5). As NSP have transformability rates up to 1,075-fold higher
than those of capsulated strains (22), NSP may act as a vector
for the transmission of resistance genes between viridans group
streptococci and capsulated pneumococci. Indeed, a serotype
19F clone became increasingly non-penicillin susceptible to by
the uptake of pbp2x gene fragments shared with NSP (10).
Despite being present in low numbers, nonencapsulated forms
of PCV7 serotypes are also likely to harbor the antibiotic
resistance genes of their parent capsular vaccine serotypes and
thus have the potential to transfer antibiotic resistance to
newly emerging nonvaccine serotypes. Our 2005 surveillance of
pneumococcal carriage by Indigenous children found that 14%
of the isolates were non-penicillin susceptible (MIC  0.12
g/ml) and that 6% of the isolates were azithromycin resistant
(MIC  2 g/ml) (15). The penicillin resistance data are in
stark contrast to the 55.5% rate of non-penicillin susceptibility
that we found in wzg-negative NSP and 26% in potentially
revertible wzg-positive NSP. Thus, there is potential for the
selection of existing capsular strains exhibiting antibiotic resis-
tance and for the uptake of resistance genes by susceptible
capsular pneumococci during exposure to NSP.
Reporting NSP in surveillance and clinical trials. High car-
riage rates, antibiotic resistance, and the presence of capsule
genes suggest a role for NSP in the maintenance and survival
of capsular pneumococci. Until this role is better understood,
we support continued reporting of NSP carriage rates. Since
MLST is necessary to explicitly confirm the identity of nonse-
rotypeable pneumococcal isolates, it will be necessary to ana-
lyze data obtained by using less rigorous methods of identifi-
cation with caution.
In populations with high NSP carriage rates, combining the
data for NSP and capsular pneumococci would inflate the rates
of pneumococcal carriage and antibiotic resistance. Therefore,
we recommend separate reporting of rates of carriage of NSP
and capsular pneumococci in surveillance studies. When the
microbiological outcomes of clinical trials are reported, we
recommend the inclusion of only the capsular pneumococci in
primary analyses.
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